Modus Advisors LLC Has $173,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Modus Advisors LLC lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 44.5% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 1,193 shares of the company’s stock after selling 955 shares during the period. Modus Advisors LLC’s holdings in Johnson & Johnson were worth $173,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Versant Capital Management Inc lifted its holdings in Johnson & Johnson by 27.8% during the 4th quarter. Versant Capital Management Inc now owns 4,678 shares of the company’s stock valued at $677,000 after purchasing an additional 1,019 shares during the last quarter. Trust Co of the South raised its position in shares of Johnson & Johnson by 5.1% in the fourth quarter. Trust Co of the South now owns 9,672 shares of the company’s stock valued at $1,399,000 after purchasing an additional 470 shares during the period. SK Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth about $234,000. Independent Solutions Wealth Management LLC grew its stake in Johnson & Johnson by 0.4% in the 3rd quarter. Independent Solutions Wealth Management LLC now owns 21,068 shares of the company’s stock valued at $3,414,000 after buying an additional 80 shares during the last quarter. Finally, Lord Abbett & CO. LLC bought a new position in Johnson & Johnson during the 3rd quarter worth approximately $69,859,000. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Performance

JNJ traded down $0.07 during midday trading on Friday, hitting $143.95. 678,400 shares of the company traded hands, compared to its average volume of 3,283,656. The company’s 50-day moving average is $152.12 and its 200 day moving average is $156.23. Johnson & Johnson has a 52 week low of $142.75 and a 52 week high of $168.85. The firm has a market capitalization of $346.58 billion, a PE ratio of 20.83, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.66 EPS. On average, research analysts expect that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.45%. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Analyst Ratings Changes

JNJ has been the topic of several recent analyst reports. Royal Bank of Canada boosted their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. Morgan Stanley upped their target price on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Finally, Bank of America restated a “neutral” rating and issued a $166.00 target price on shares of Johnson & Johnson in a report on Tuesday, December 10th. Seven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $174.73.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.